Cognitive Impairment in Heart Failure: A Heart Failure Society of America Scientific Statement
Cognitive impairment is common among adults with heart failure (HF), as both diseases are strongly related to advancing age and multimorbidity (including both cardiovascular and noncardiovascular conditions). Moreover, HF itself can contribute to alterations in the brain. Cognition is critical for a myriad of self-care activities that are necessary to manage HF, and it also has a major impact on prognosis; consequently, cognitive impairment has important implications for self-care, medication management, function and independence, and life expectancy. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 1, 2024 Category: Cardiology Authors: PARAG GOYAL, ROBERT J. DIDOMENICO, SUSAN J. PRESSLER, CHINWE IBEH, CONNIE WHITE-WILLIAMS, LARRY A. ALLEN, EIRAN Z. GORODESKI, HFSA Scientific Statement Committee Members Tags: Review Article Source Type: research
Editorial Board
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 1, 2024 Category: Cardiology Source Type: research
Table of Contents
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 1, 2024 Category: Cardiology Source Type: research
Masthead
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 1, 2024 Category: Cardiology Source Type: research
Cognitive Impairment Is Our Job Too
It is recommended that heart failure (HF) clinicians spend time providing education about HF, which medications to take and why, and self-care critical to HF management such as checking daily weights and how to respond to fluctuations, self-management of diuretics, and reading food labels and limiting salt intake. Intent on integrating this information, our patients try their best to listen, process, understand, and retain the information that we share. Yet medication errors and suboptimal self-care are common, and frequently contribute to hospitalizations and reduced quality of life. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 1, 2024 Category: Cardiology Authors: Eiran Z. Gorodeski, Parag Goyal Tags: Editor's Page: We've been thinking … Source Type: research
The Future of Durable Mechanical Circulatory Support: Emerging Technological Innovations and Considerations to Enable Evolution of the Field
The field of durable mechanical circulatory support (MCS) has undergone an incredible evolution over the past few decades, resulting in significant improvements in longevity and quality of life for patients with advanced heart failure. Despite these successes, substantial opportunities for further improvements remain, including in pump design and ancillary technology, perioperative and postoperative management, and the overall patient experience. Ideally, durable MCS devices would be fully implantable, automatically controlled, and minimize the need for anticoagulation. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 29, 2024 Category: Cardiology Authors: Seraina A. Dual, Jennifer Cowger, Ellen Roche, Aditi Nayak Tags: Review Article Source Type: research
The Future of Durable Mechanical Circulatory Support – Emerging Technological Innovations and Considerations to Enable Evolution of the Field
The field of durable mechanical circulatory support (MCS) has undergone an incredible evolution over the past few decades, resulting in significant improvements in longevity and quality of life for advanced heart failure patients. Despite these successes, substantial opportunities for further improvements remain, including in pump design and ancillary technology, peri- and post-operative management, and the overall patient experience. Ideally, durable MCS devices would be fully implantable, automatically controlled, and minimize need for anticoagulation. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 29, 2024 Category: Cardiology Authors: Seraina A. Dual, Jennifer Cowger, Ellen Roche, Aditi Nayak Tags: Review Article Source Type: research
The Effectiveness of Lifestyle Interventions in Heart Failure with Preserved Ejection Fraction: A Systematic review and Network Meta-Analysis
Globally as of 2019, there was an estimated 56.19 million prevalent cases of HF 1. In the United Kingdom (UK) approximately 920,000 are living with heart failure (HF)2 with an estimated 50% having HF with preserved ejection fraction (HFpEF). HFpEF is a heterogenous syndrome with a complex aetiology often associated with metabolic comorbidities -including obesity and type 2 diabetes mellitus (T2DM)3 and it is typified by severe exercise intolerance.4 People with HFpEF have a substantially reduced exercise tolerance (peak oxygen uptake (V ̇O2peak) is ∼35% lower vs healthy controls)5-11, which is associated with poor outco...
Source: Journal of Cardiac Failure - February 28, 2024 Category: Cardiology Authors: Grace WM Walters, Jian L Yeo, Joanna M. Bilak, Coral Pepper, Gaurav S Gulsin, Suzanne C Freeman, Laura J Gray, Gerry P McCann, Emer M Brady Source Type: research
Patient Focus: A Prescription to Move. An Explanation of The Effectiveness of Lifestyle Interventions in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis
In this issue of the Journal of Cardiac Failure, Dr. Grace Walters and colleagues look at which lifestyle interventions in the treatment of heart failure with preserved ejection fraction can best improve exercise tolerance, functional capacity and overall quality of life.1 (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 27, 2024 Category: Cardiology Authors: ANAS JAWAID, JENNIFER T. THIBODEAU Source Type: research
Patient Focus: A Prescription to Move. An explanation of “The Effectiveness of Lifestyle Interventions in Heart Failure with Preserved Ejection Fraction: A Systematic review and Network Meta-Analysis’’
In this issue of the Journal of Cardiac Failure, Dr. Grace Walters and colleagues look at which lifestyle interventions in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) can best improve exercise tolerance, functional capacity, and overall quality of life (1). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 27, 2024 Category: Cardiology Authors: Anas Jawaid, Jennifer T. Thibodeau Source Type: research
Settling the IRONy of Anemia in Heart Failure: Current Evidence and Future Directions
The prevalence of anemia may reach as high as 50% in patients with heart failure (HF) and incident anemia is noted at 1-year follow-up in 25% of those with normal baseline hemoglobin (Hgb) value1. Although anemia has been linked to the severity of HF and even mortality2,3, some reports suggest that the association is no longer significant when controlling for one of the most common underlying etiology, iron deficiency4. Iron is indispensable for Hgb biosynthesis but anemia due to iron deficiency is a late presentation affecting approximately 50% of patients4,5. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 22, 2024 Category: Cardiology Authors: Adamantios Tsangaris, Andrew P. Ambrosy, Michael Tschida, Tamas Alexy Tags: Editorial Comment Source Type: research
Safety indicators in the STRONG-HF trial from a methodological perspective
Acute heart failure (AHF) is associated with an increased risk of post-discharge clinical outcomes.1 In patients recently hospitalized for AHF, the Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies (STRONG-HF) trial showed that a high intensity care (HIC) strategy of rapid up-titration of guideline-directed medication (GDMT) and close follow-up reduce the risk of 180-day HF readmission or all-cause death, compared with usual care (UC). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 20, 2024 Category: Cardiology Authors: Xavier Rossello Tags: Editorial Comment Source Type: research
Modes of Death in Patients with Cardiogenic Shock in the Cardiac Intensive Care Unit: A Report from the Critical Care Cardiology Trials Network
There are limited data on how patients with cardiogenic shock (CS) die. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 20, 2024 Category: Cardiology Authors: David D. Berg, Sachit Singal, Michael Palazzolo, Vivian M. Baird-Zars, Fadel Bofarrag, Erin A. Bohula, Sunit-Preet Chaudhry, Mark W. Dodson, Dustin Hillerson, Patrick R. Lawler, Shuangbo Liu, Connor G. O'Brien, Barbara A. Pisani, Lekha Racharla, Robert O. Tags: Brief Report Source Type: research
Outcomes of Patients with Cardiogenic Shock in Hub and Spoke Centers: The importance of Protocol Standardization at a Network Level
Despite advances in therapies and understanding of the phenotypes of cardiogenic shock (CS), mortality from this condition remains elevated[1]. Randomized clinical trials have demonstrated that the only therapies that improve survival in acute myocardial infarction CS (AMI-CS) are early revascularization[2] and culprit-only revascularization in AMI-CS with multivessel coronary disease[3]. More recently, non-randomized data suggested improvements in survival with multidisciplinary CS teams[4 –6]. However, the presence of CS teams is often limited to tertiary hospitals and referral centers with comprehensive CS programs. (...
Source: Journal of Cardiac Failure - February 15, 2024 Category: Cardiology Authors: Carlos L. Alviar, Sylvie Hall, Alexandre Mebazaa Tags: Editorial Comment Source Type: research
Patient and Provider Factors Associated With Initiating Sodium-Glucose Cotransporter-2 Inhibitors (SGTL2i) Following FDA Approval for Heart Failure with Preserved and Mildly Reduced Ejection Fraction
Although the implementation gap in guideline-directed medical therapy (GDMT) is well described in heart failure with reduced ejection fraction (HFrEF), it is not well characterized in patients with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) (1). As evidence grows for the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) across the ejection fraction (EF) spectrum, it is critical to understand where uptake lags (2,3). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 15, 2024 Category: Cardiology Authors: Trejeeve Martyn, Joshua Saef, Agam Bansal, Kathryn A. Martinez, Hunter Block-Beach, Jessica Hohman, Samir R. Kapadia, Milind Y. Desai, Jerry D. Estep, Nancy M. Albert, Randall C. Starling, W.H. Wilson Tang Tags: Research Letter Source Type: research
